Sign in Create account

Gennex Laboratories Ltd

Healthcare · Pharmaceuticals & Biotechnology

BSE: 531739
₹9.95
▼ -0.13 (-1.29%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
58/100
Moderate
Valuation
89/100
Undervalued
Momentum
45/100
Neutral

QVM read Cheap on its own multiples Quality Moderate, Valuation Undervalued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹242 Cr
PE (TTM)
15.1
Industry median 36.1 (152 companies)
Price to Book
1.0
PEG (TTM)
-1.6
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-37.9
Free Cash Flow
₹-76 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-11.11%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-4.51%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
32.97%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-4.70%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
35.25%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
3.66
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.15
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
8.38
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
11.40%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
13.59%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
15.50%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
5.89%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
9.34%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
7.39%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 7 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.15)
  • No Return on equity is 15% or more (7.4%)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

1 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • No Promoter pledge is 5% of their holding or less and not rising (21.8% pledged)

Peer comparison

1 of 3 met
  • No 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

2 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Undervalued (below its own historical PE range))
  • Yes Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-1.3%
Low 9.9100 · High 10.2800
1W return
-3.6%
Low 9.8000 · High 10.9000
1M return
-21.2%
Low 9.8000 · High 12.9300
52W return
-37.9%
Low 8.7500 · High 13.2500
Lifetime High ₹55.8000 (Aug. 13, 2008)
Lifetime Low ₹0.6200 (Aug. 27, 2013)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish0
Bearish6
5D
10.1
10D
10.3
20D
10.7
50D
12.0
100D
13.5
200D
15.8

Delivery and volume

Day avg. delivery
72.3%
Week avg. delivery
75.4%
Month avg. delivery
77.6%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

10.05
Pivot
First resistance10.18
Second resistance10.42
Third resistance10.55
First support9.81
Second support9.68
Third support9.44
Day RSI34.5
Day MFI38.1
Day MACD-0.62
Day MACD signal-0.62

Beta

1M1.90
3M1.69
1Y1.69
3Y0.59

Price change analysis

↓ -21.2%
Over 1 Month
LowHigh
9.8012.93
↓ -37.9%
Over 3 Months
LowHigh
8.7513.25
↓ -37.9%
Over 6 Months
LowHigh
8.7513.25
↓ -37.9%
Over 1 Year
LowHigh
8.7513.25
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 15.1 (own history: 20.1–31.1)
Undervalued (below its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹35 Cr
Net profit (June 30, 2026)
₹4 Cr
Basic EPS (June 30, 2026)
₹0.1600

Ranks #113 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter23.63%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 23.63% in Jun 2026 qtr

All shareholding details →

Deals (Bulk & Block)

All 296 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
22 May 2026 ANUPRIYA CONSULTANTS PVT LTD Bulk Sell 625,000 12.3000 BSE
22 May 2026 ANUPRIYA CONSULTANTS PVT LTD Bulk Buy 1,275,000 11.9200 BSE
19 May 2026 ANUPRIYA CONSULTANTS PVT LTD Bulk Buy 1,934,782 9.9700 BSE
15 Oct 2025 KAMAL KUMAR DUGAR AND CO ( PROP : KAMAL KUMAR DUGAR) Bulk Sell 1,175,000 13.8100 BSE
15 Oct 2025 DORITE TRACON PRIVATE LIMITED Bulk Buy 1,501,719 13.7500 BSE
14 Oct 2025 NARANTAK DEALCOMM LIMITED Bulk Buy 2,000,000 13.3700 BSE
30 Sep 2025 TROPICAL AGRO SYSTEM INDIA PRIVATE LIMITED Bulk Sell 1,700,000 11.0100 BSE
12 Mar 2025 MARYADA BARTER PRIVATE LIMITED Bulk Buy 1,207,467 12.7300 BSE
18 Oct 2024 KAMAL KUMAR DUGAR AND CO ( PROP : KAMAL KUMAR DUGAR) Bulk Sell 1,174,666 22.6200 BSE
10 Oct 2024 L7 HITECH PRIVATE LIMITED Bulk Sell 2,452,005 22.8700 BSE

All bulk and block deals →

Corporate Actions

Full history (1 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from Prudential Pharmaceuticals Limited to Gennex Laboratories Limited

All corporate actions →

Corporate Announcements

All 8 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
1 Oct 2026 AGM/EGM Gennex Laboratories Ltd - 531739 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
30 Sep 2026 AGM/EGM Gennex Laboratories Ltd - 531739 - Shareholder Meeting / Postal Ballot-Outcome of AGM
30 Sep 2026 Company Update Gennex Laboratories Ltd - 531739 - Announcement under Regulation 30 (LODR)-Change in Management
9 Sep 2026 Company Update Gennex Laboratories Ltd - 531739 - Announcement under Regulation 30 (LODR)-Newspaper Publication
8 Sep 2026 Company Update Gennex Laboratories Ltd - 531739 - Approval Of Additional Products From Drugs Control Administration, Government Of Andhra Pradesh For Our Subsidiary Company, Deccan Remedies Limited
8 Sep 2026 Others Gennex Laboratories Ltd - 531739 - Reg. 34 (1) Annual Report.
4 Sep 2026 Board Meeting Gennex Laboratories Ltd - 531739 - Board Meeting Outcome for Meeting Held On September 04, 2026
4 Sep 2026 Corp. Action Gennex Laboratories Ltd - 531739 - Intimation Of Book Closure For The Purpose Of 41St AGM Of Gennex Laboratories Limited

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.15)
  • Strong revenue growth YoY (35.2%)

Weaknesses

  • Low Return on Equity (7.4%)
  • Declining profit YoY (-4.7%)

Opportunities

Data unavailable.

Threats

  • Down 37.9% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Gennex Laboratories Ltd

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.